1. Life-course socioeconomic disadvantage and lung function: a multicohort study of 70 496 individuals
- Author
-
Carla Moreira, Graham G. Giles, Alexandra Lenoir, Silvia Stringhini, Peter Vollenweider, Paolo Vineis, Vânia Rocha, Henrique Barros, Marcel Goldberg, Andrew Steptoe, Mika Kivimäki, Sílvia Fraga, Cristian Carmeli, Marie Zins, ISPUP-EPIUnit [Porto, Portugal], Universidade do Porto = University of Porto, University of Minho [Braga], Université de Fribourg = University of Fribourg (UNIFR), Lausanne University Hospital, University College of London [London] (UCL), Cancer Council Victoria [Melbourne, VIC, Australia], Cohortes épidémiologiques en population (CONSTANCES), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université Paris Cité (UPCité), Université Paris Descartes, Sorbonne Paris Cité, Imperial College London, Université de Lausanne = University of Lausanne (UNIL), Geneva University Hospital (HUG), This work was supported by European regional development fund through the Operational Programme Competitiveness and Internationalisation and national funding from the Foundation for Science and Technology (FCT, Portuguese Ministry of Science, Technology and Higher Education) under the EPIUnit, Instituto de Saúde Pública da Universidade do Porto, Portugal (POCI-01-0145-FEDER-006862, reference: UID/DTP/04750/2019). It is also supported by the European Commission (Horizon 2020 grant number 633666), PhD grant SFRH/BD/103726/ 2014 (V. Rocha) co-funded by FCT and the POCH/FSE Program, FCT contract CEECIND/01516/2017/CP1406/CT0001 (S. Fraga), and by the University of Lausanne (Pro-Femmes grant, S. Stringhini). M. Kivimaki was supported by the Medical Research Council (K013351, R024227), the US National Institute on Aging (R01AG056477), NordForsk, the Academy of Finland (311492), and Helsinki Institute of Life Science during the conduct of the study. The CoLaus|PsyCoLaus study is supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 3200B0_105993, 3200B0_118308, 33CSCO_122661, 33CS30_139468 and 33CS30_14840). The Constances cohort is supported by the Caisse nationale d’assurance maladie and by a grant from the Agence nationale de la recherche (ANR-11-INBS-0002). Funding information for this article has been deposited with the Crossref Funder Registry., Jan Alberts, Harri Alenius, Mauricio Avendano, Laura Baglietto, Valeria Baltar, Henrique Barros, Mel Bartley, Michele Bellone, Eloise Berger, David Blane, Murielle Bochud, Giulia Candiani, Cristian Carmeli, Luca Carra, Raphaele Castagne, Marc Chadeau-Hyam, Sergio Cima, Giuseppe Costa, Emilie Courtin, Cyrille Delpierre, Angelo D'Errico, Angela Donkin, Pierre-Antoine Dugue, Paul Elliott, Guy Fagherazzi, Giovanni Fiorito, Silvia Fraga, Martina Gandini, Valérie Gares, Pascale Gerbouin-Rerolle, Graham Giles, Marcel Goldberg, Dario Greco, Allison Hodge, Maryam Karimi, Piia Karisola, Michelle Kelly-Irving, Mika Kivimaki, Jessica Laine, Thierry Lang, Audrey Laurent, Richard Layte, Benoit Lepage, Dori Lorsch, Giles Machell, Johan Mackenbach, Michael Marmot, Cathal McCrory, Carlos de Mestral, Cynthia Miller, Roger Milne, Peter Muennig, Wilma Nusselder, Dusan Petrovic, Lourdes Pilapil, Silvia Polidoro, Martin Preisig, Ana Isabel Ribeiro, Fulvio Ricceri, Paolo Recalcati, Erica Reinhard, Oliver Robinson, Jose Rubio Valverde, Severine Saba, Frank Santegoets, Gianluca Severi, Terrence Simmons, Silvia Stringhini, Adam Tabak, Vesa Terhi, Joannie Tieulent, Salvatore Vaccarella, Federica Vigna-Taglianti, Paolo Vineis, Peter Vollenweider, Marie Zins, European Project: 633666,H2020,H2020-PHC-2014-two-stage,LIFEPATH(2015), Instituto de Saúde Pública da Universidade do Porto, University of Fribourg, Demarquay, Sandrine, and Lifecourse biological pathways underlying social differences in healthy ageing - LIFEPATH - - H20202015-05-01 - 2019-04-30 - 633666 - VALID
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,Vital capacity ,[SDV]Life Sciences [q-bio] ,Vital Capacity ,030204 cardiovascular system & hematology ,Lung ,03 medical and health sciences ,FEV1/FVC ratio ,0302 clinical medicine ,Risk Factors ,Forced Expiratory Volume ,medicine ,Humans ,030212 general & internal medicine ,Socioeconomic status ,Aged ,ddc:616 ,business.industry ,Middle Aged ,respiratory system ,medicine.disease ,Obesity ,respiratory tract diseases ,Respiratory Function Tests ,Disadvantaged ,[SDV] Life Sciences [q-bio] ,Institutional repository ,medicine.anatomical_structure ,Socioeconomic Factors ,Life course approach ,Female ,business ,Demography - Abstract
Background Lung function is an important predictor of health and a marker of physical functioning at older ages. This study aimed to quantify the years of lung function lost according to disadvantaged socioeconomic conditions across the life-course. Methods This multicohort study used harmonised individual-level data from six European cohorts with information on life-course socioeconomic disadvantage and lung function assessed by forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC). 70 496 participants (51% female) aged 18–93 years were included. Socioeconomic disadvantage was measured in early life (low paternal occupational position), early adulthood (low educational level) and adulthood (low occupational position). Risk factors for poor lung function (e.g. smoking, obesity, sedentary behaviour, cardiovascular and respiratory diseases) were included as potential mediators. The years of lung function lost due to socioeconomic disadvantage were computed at each life stage. Results Socioeconomic disadvantage during the life-course was associated with a lower FEV1. By the age of 45 years, individuals experiencing disadvantaged socioeconomic conditions had lost 4–5 years of healthy lung function versus their more advantaged counterparts (low educational level −4.36 (95% CI −7.33–−2.37) for males and −5.14 (−10.32–−2.71) for females; low occupational position −5.62 (−7.98–−4.90) for males and −4.32 (−13.31–−2.27) for females), after accounting for the risk factors for lung function. By the ages of 65 years and 85 years, the years of lung function lost due to socioeconomic disadvantage decreased by 2–4 years, depending on the socioeconomic indicator. Sensitivity analysis using FVC yielded similar results to those using FEV1. Conclusion Life-course socioeconomic disadvantage is associated with lower lung function and predicts a significant number of years of lung function loss in adulthood and at older ages. This work was supported by European regional development fund through the Operational Programme Competitiveness and Internationalisation and national funding from the Foundation for Science and Technology (FCT; Portuguese Ministry of Science, Technology and Higher Education) under the EPIUnit, Instituto de Saúde Pública da Universidade do Porto, Portugal (POCI-01-0145-FEDER-006862; reference: UID/DTP/04750/2019). It is also supported by the European Commission (Horizon 2020 grant number 633666), PhD grant SFRH/BD/103726/2014 (V. Rocha) co-funded by FCT and the POCH/FSE Program, FCT contract info:eu-repo/grantAgreement/FCT/CEEC IND 2017/CEECIND/01516/2017/CP1406/CT0001/PT/CP1406/CT0001 (S. Fraga), and by the University of Lausanne (Pro-Femmes grant, S. Stringhini). M. Kivimaki was supported by the Medical Research Council (K013351, R024227), the US National Institute on Aging (R01AG056477), NordForsk, the Academy of Finland (311492), and Helsinki Institute of Life Science during the conduct of the study. The CoLaus|PsyCoLaus study is supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 3200B0_105993, 3200B0_118308, 33CSCO_122661, 33CS30_139468 and 33CS30_14840). The Constances cohort is supported by the Caisse nationale d'assurance maladie and by a grant from the Agence nationale de la recherche (ANR-11-INBS-0002). Funding information for this article has been deposited with the Crossref Funder Registry.
- Published
- 2021
- Full Text
- View/download PDF